Gene Therapy for HER-Positive Cancer (SENTRY-HER2)

Clinical trial NCT07192432 · RECRUITING

Trial details

NCT number: NCT07192432
Sponsor: Vironexis Biotherapeutics Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

HER2 Expressing Solid Tumors

Start date: 2025-11-18
Primary completion: 2033-09-01
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.